About this episode

Kayla Ellsworth discusses the challenges in drug development and the transformative role of New Approach Methodologies.

Kayla Ellsworth explores why nearly 90% of drug candidates fail and how New Approach Methodologies (NAMs) are transforming drug development. She explains how technologies like AI, omics, advanced in vitro models, and microphysiological systems better replicate human biology, improving research while reducing reliance on animal testing. The conversation also highlights the importance of innovation, women in leadership, and emerging technologies such as brain-on-a-chip that are shaping the future of healthcare. Chapters: 00:00 The Drug Development Crisis 09:08 Introducing New Approach Methodologies (NAMS) 17:53 Exploring NAMS: In Silico to Microphysiological Systems 25:19 Dynamic Microphysiological Systems 26:39 Evidence of Effectiveness in Drug Development 28:48 Speeding Up Drug Development Processes 30:42 Integrating New Approaches in Drug Development 32:17 The Future of Animal Testing 34:21 Women in Leadership and Industry 39:43 Role of Speccro in Drug Development 42:35 Innovations on the Horizon Guest Information: Guest's Name: Kayla Ellsworth Guest's Title/Position: Scientific Operations Coordinator LinkedIn: https://www.linkedin.com/in/kayla-ellsworth-18a2841a0/ Company /…

People in this episode

Host: Heath Fletcher

Guest: Kayla Ellsworth

Topics covered

• drug development
• New Approach Methodologies
• AI in healthcare
• women in leadership
• innovation in drug research

Keywords

• drug candidates
• NAMs
• human biology
• animal testing
• brain-on-a-chip

Mentioned in this episode

Organizations: SPECCRO

More episodes of The Healthy Enterprise

• 90% of Drug Developments Fail — Why That's About to Change! · June 19, 2026 · 46 min

Explore listener stats, chart rankings, contacts and more on the The Healthy Enterprise podcast page.